Clinical research is a challenging task. An organization inevitably encounters some setbacks, but clinical trial technology should never be one of them. Clinical trial management is made easier using YPrime solutions. YPrime develops its technologies on cutting-edge platforms and adheres to the strictest quality standards. Their experienced team, which includes designers, developers, managers, and support technicians, all strive toward the same goal: providing the best possible experience for sponsors, sites, and patients. YPrime innovates through embracing pragmatic, forward-thinking change that takes into account the demands of all stakeholders involved in clinical research. They understand that breakthroughs aren’t magic. They’re the culmination of years of hard work and incremental improvements.

YPrime has more than a decade of experience working with eclinical systems to enhance patient management, clinical supplies, medication accountability, and clinical data quality. Sponsors can benefit from cloud-based interactive response technology (IRT) and electronic clinical outcome assessment (eCOA) technologies that improve clinical trial management speed, precision, and integration. Their data services and solutions assist sponsors in combining disparate clinical research data into actionable context information. Sponsors may advance quicker and more efficiently to their next development milestone with YPrime’s technology and service solutions. YPrime assists an organization in deciphering clinical trial complexity by providing IRT solutions that anticipate the clinical research industry’s ever-changing demands. Their clients can decrease the risks, hassles, complexity, workload, time, and costs of managing all elements of global patient randomization and clinical supply management by utilizing YPrime’s IRT platform. In the rare case of device breakdown, loss, or when patients are unable to travel to investigator locations, YPrime’s web-based backup solutions allow ongoing data gathering. Patients can complete evaluations in the case of device loss or malfunction using web-based systems that allow access to site-based electronic patient-reported outcome (ePRO) assessments, clinician-reported outcome (ClinRO) assessments, and field-based assessments.

For sponsors, investigator sites, and patients, YPrime’seCOA platform provides an unparalleled user experience. This cutting-edge technology improves the efficiency of clinical trials as well as site satisfaction and patient compliance. The eCOA platform from YPrime enables the delivery of cleaner data, reducing the time it takes to gather and approve clinical trial data. Even the most sophisticated protocols are delivered with ease by YPrime’s platform. All techniques are available for site-or home-based trials and have been designed to connect smartly with the current technology. The eCOA platform from YPrime has a simple design that helps patients stay engaged and compliant. Sites may move between devices and input data more precisely and efficiently, resulting in higher-quality data while staying on schedule and under budget. Sponsors benefit from real-time data access since it gives them more control over their projects and allows them to make better decisions. With the added security of an industry-leading online backup solution, the platform provides higher processing power and additional security measures. “With a 15-year track record as a technology leader, we are constantly innovating to help drive the digital transformation of clinical research,” says YPrime Co-Founder and CEO Shawn Blackburn. “The rapid shift toward a more patient-centered approach to clinical trials is enabled by the strength of our eCOA platform.”

Tryl, a software development business, was recently bought by YPrimein order to enhance its experience in supporting decentralized clinical trials. To improve participation, reduce dropouts, and offer outcomes in clinical trials, Tryl’s patient engagement solution blends personalization with applied behavioral science. As a result of the acquisition, YPrime will receive access to all ofTryl’s development knowledge, employees, and intellectual property as a result of the acquisition, and will combine it with the latter’s Patient Engagement Technologies offerings. Tryl’s products provide a personalized, predictive, and relative experience throughout the patient’s whole trip.

Thus, YPrime’s objective is to assist their clients in the timely and correct completion of creative research that advances their drug development initiatives to the next step.